Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1937809 | 1.00 | MEN1 (0.43) | MEN1KMT2ATDP1POLBHSP90AA1 | |
| SCHEMBL2181537 | 0.82 | MAPT (0.48) | KMT2AHSP90AA1MAPK1CYP19A1MAPT | |
| SCHEMBL1938264 | 0.82 | MAPT (0.48) | KMT2AHSP90AA1MAPK1CYP19A1MAPT | |
| SCHEMBL10669435 | 0.81 | MEN1 (0.49) | MEN1KMT2ATDP1POLBHSP90AA1 | |
| SCHEMBL10669426 | 0.81 | MEN1 (0.49) | MEN1KMT2ATDP1POLBHSP90AA1 | |
| SCHEMBL2180573 | 0.81 | MEN1 (0.47) | MEN1KMT2ATDP1POLBHSP90AA1 | |
| SCHEMBL1937172 | 0.81 | MEN1 (0.47) | MEN1KMT2ATDP1POLBHSP90AA1 | |
| SCHEMBL12437870 | 0.77 | KMT2A (0.48) | MEN1KMT2ATDP1POLBHSP90AA1 | |
| SCHEMBL2170715 | 0.73 | MAPK1 (0.44) | MEN1KMT2ATDP1MAPK1CYP19A1 | |
| SCHEMBL2161013 | 0.73 | MAPK1 (0.52) | MEN1KMT2ATDP1POLBHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166021-A1 | Imidazole and Triazole Compounds, the Use Thereof and Preparations Containing These Compounds | BASF SE (DE) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166021-A1 | Imidazole and Triazole Compounds, the Use Thereof and Preparations Containing These Compounds | NISCH, CYP3A5, CYP11B2 | MEN1 718/4885KMT2A 2143/4885TDP1 813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.